Providence Health & Services — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Providence Health & Services appears in 43 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials43

Recruiting shown4

Roles2

SourceClinicalTrials.gov

Clinical trials

43 shown

CAN1012 in Pre-Malignant DCIS and LCISNCT07408856 · lead sponsor · 2026-09-16

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC PatientsNCT06353997 · lead sponsor · 2024-09-05

Clinical Outcomes and Patient Satisfaction With Use of the Amma SystemNCT05508984 · lead sponsor · 2022-08-22

ACTIVE_NOT_RECRUITING

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating MedicationNCT04796584 · lead sponsor · 2022-07-11

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.NCT04896320 · lead sponsor · 2021-12-15

Sema 4A as a Marker for Inflammatory Disease in Multiple SclerosisNCT05077956 · lead sponsor · 2021-10-19

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast CancerNCT04895761 · lead sponsor · 2021-09-10

ACTIVE_NOT_RECRUITING

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerNCT04373031 · lead sponsor · 2020-12-30

ACTIVE_NOT_RECRUITING

A Systems Approach to Understanding Disease Processes in Multiple SclerosisNCT05081700 · lead sponsor · 2020-05-11

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to OcrelizumabNCT04175834 · lead sponsor · 2020-02-05

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsNCT03650894 · lead sponsor · 2019-04-03

ACTIVE_NOT_RECRUITING

Melatonin in Patients With Multiple Sclerosis (MS).NCT03498131 · lead sponsor · 2018-05-09

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer PatientsNCT03289364 · lead sponsor · 2017-08-24

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to OcrelizumabNCT03157830 · lead sponsor · 2017-06-01

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)NCT02950259 · lead sponsor · 2017-02-09

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsNCT02575404 · lead sponsor · 2016-05-16

Standard of Care Chemotherapy Plus Pembrolizumab for Breast CancerNCT02734290 · lead sponsor · 2016-02-23

ACTIVE_NOT_RECRUITING

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)NCT02422381 · lead sponsor · 2015-07-20

ACTIVE_NOT_RECRUITING

ACTH for Fatigue in Multiple Sclerosis PatientsNCT02315872 · lead sponsor · 2015-05-22

Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer PatientsNCT02688725 · lead sponsor · 2014-12-01

Telemedicine Technology Demonstration Project for Heart FailureNCT02115620 · lead sponsor · 2014-03-23

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCVNCT01970410 · lead sponsor · 2013-10-01

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)NCT01909492 · lead sponsor · 2013-09-20

Comparison Study of Insulin Glargine and NPH InsulinNCT01854723 · lead sponsor · 2013-04-01

Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure PatientsNCT01822171 · lead sponsor · 2013-01-01

Prevalence, Awareness and Management of Hypertension in Acute Care PersonnelNCT01655654 · lead sponsor · 2012-08-01

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic LesionsNCT01862900 · lead sponsor · 2012-04-27

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate CancerNCT01303705 · lead sponsor · 2010-10-14

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)NCT01057212 · lead sponsor · 2010-02-01

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung CancerNCT00850785 · lead sponsor · 2009-01-01

GVAX in Advanced Prostate Cancer Patients Made LymphopenicNCT00122005 · lead sponsor · 2005-07-01

Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung CancerNCT00232206 · lead sponsor · 2005-05-01

Angiotensin II Antagonism of TGF-Beta 1NCT00320970 · lead sponsor · 2002-08-01

Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility TrialNCT06626152 · collaborator · 2024-08-15

Kidney Precision Medicine ProjectNCT04334707 · collaborator · 2019-09-01

Using Clinical Prediction Models to Improve Treatment for Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT05309356 · collaborator · 2023-03-21

The Care Ecosystem Consortium Effectiveness StudyNCT05669365 · collaborator · 2023-01-17

Pilot Study of DRibble Vaccine for Prostate Cancer PatientsNCT02234921 · collaborator · 2014-10-24

Asthma Self-management Via Application of TelehealthNCT02017795 · collaborator · 2014-08-01

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung CancerNCT01909752 · collaborator · 2013-07-01

Chronic Obstructive Pulmonary Disease Biomarker StudyNCT02050022 · collaborator · 2013-04-01

The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast ReconstructionNCT01427400 · collaborator · 2011-10-01

Mastectomy Reconstruction Outcomes Consortium (MROC) StudyNCT01723423 · collaborator · 2011-08-01

Drugs studied in this sponsor's trials

19 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Providence Health & Services as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

cyclophosphamide4

pembrolizumab4

imiquimod2

bevacizumab1

bicalutamide1

candesartan1

capecitabine1

corticotropin1

cyclophosphamide RxCUI 3002 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 4 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 4 trials imiquimod RxCUI 59943 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bicalutamide RxCUI 83008 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial candesartan RxCUI 214354 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial capecitabine RxCUI 194000 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial corticotropin RxCUI 376 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial diphenhydramine RxCUI 3498 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial indomethacin RxCUI 5781 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ipilimumab RxCUI 1094833 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ixabepilone RxCUI 337523 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nivolumab RxCUI 1597876 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial omeprazole RxCUI 7646 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial teriflunomide RxCUI 1310520 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial tucatinib RxCUI 2361285 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor33

collaborator10

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.